Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study.

Trial Profile

Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Dec 2011

At a glance

  • Drugs Pegaptanib (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms PRESERVE
  • Most Recent Events

    • 05 Dec 2011 Actual initiation date (Apr 2009) added, primary endpoint identified as Best Corrected Visual Acuity, actual patient number is 72, additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 05 Dec 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01486238).
    • 05 Dec 2011 Official Title amended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top